CPhl China 2023 Invitation

2023/04/20

Related News

Beilu Pharmaceutical Intends to Establish a Wholly-owned Subsidiary in Hong Kong
December 27, 2022In order to further expand overseas markets and meet the needs of the company's strategic development, Beilu Pharmaceutical intends to establish a wholly-owned subsidiary in Hong Kong.Actively exp...view
To Understand the Development of Iodinated Contrast Agents
May 13, 2021For the purpose of medical imaging, a certain substance is introduced into the human body to change the image contrast of the body's local tissues.view
Beilu was Awarded the Title of A-class enterprise for safety production
February 1, 2023Recently, Beijing Beilu Pharmaceutical Co., Ltd. was once again awarded the title of "Class A Unit for Safety Production" in Miyun Park of Zhongguancun District. The company has won this awa...view
Beilu Pharma's Subsidiary, Hichi Pharmaceutical, Obtains Korean Registration for Iohexol.
September 21, 2023Beilu Pharmaceutical's subsidiary, Zhejiang Hichi Pharmaceutical, has recently obtained the certificate of registration for Iohexol API from the Ministry of Food and Drug Safety in Korea.This regi...view
Beilu's Gadopentetate Dimeglumine Injection Passed the Quality and Efficacy of Generic Drugs Consistency Evaluation
July 27, 2021Recently, our company received the“Drug Supplementary Application Approval Notice”(Notice Number: 2021B02267, 2021B02268) for two specifications of Gadopentetate Dimeglumine Injection.view
Knowledge About Non Ionic Contrast Medium
October 27, 2021Non ionic contrast medium is the second generation of CT contrast medium. Compared with the first generation of ionic contrast medium, the non ionic contrast medium has greater water solubility. In ad...view

CPhl China 2023 Invitation

Beilu Pharmaceutical Intends to Establish a Wholly-owned Subsidiary in Hong Kong

To Understand the Development of Iodinated Contrast Agents

Beilu was Awarded the Title of A-class enterprise for safety production

Beilu Pharma's Subsidiary, Hichi Pharmaceutical, Obtains Korean Registration for Iohexol.

Beilu's Gadopentetate Dimeglumine Injection Passed the Quality and Efficacy of Generic Drugs Consistency Evaluation

Knowledge About Non Ionic Contrast Medium